Does the media prefer BBIO or ELVN?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.23 beat BridgeBio Pharma's score of 0.99 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 7 mentions for Enliven Therapeutics and 5 mentions for Ascendis Pharma A/S. Enliven Therapeutics' average media sentiment score of 1.23 beat Ascendis Pharma A/S's score of 0.68 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELVN or EXEL?

In the previous week, Exelixis had 19 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Exelixis and 7 mentions for Enliven Therapeutics. Exelixis' average media sentiment score of 1.34 beat Enliven Therapeutics' score of 1.23 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or ELVN?

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 7 mentions for Enliven Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 1.32 beat Enliven Therapeutics' score of 1.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or ELVN?

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.23 beat Arrowhead Pharmaceuticals' score of 1.18 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 15 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$60.50 -0.37 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$62.00 +1.50 (+2.48%)

As of 07:30 PM Eastern

Compare

ELVN vs. BBIO, ASND, EXEL, BMRN, and ARWR

Should you buy Enliven Therapeutics stock or one of its competitors? Enliven Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enliven Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Enliven Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Enliven Therapeutics	N/A	-18.55%	-18.09%

BridgeBio Pharma currently has a consensus target price of $100.79, suggesting a potential upside of 28.10%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 23.97%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 6 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.23 beat BridgeBio Pharma's score of 0.99 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Enliven Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	30.63	-$724.93M	-$3.57	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

BridgeBio Pharma beats Enliven Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 7 mentions for Enliven Therapeutics and 5 mentions for Ascendis Pharma A/S. Enliven Therapeutics' average media sentiment score of 1.23 beat Ascendis Pharma A/S's score of 0.68 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.10	-$258M	$12.89	19.35
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Ascendis Pharma A/S presently has a consensus price target of $302.68, indicating a potential upside of 21.38%. Enliven Therapeutics has a consensus price target of $75.00, indicating a potential upside of 23.97%. Given Enliven Therapeutics' higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Ascendis Pharma A/S has a net margin of 70.99% compared to Enliven Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Summary

Ascendis Pharma A/S beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Exelixis?

Enliven Therapeutics (NASDAQ:ELVN) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Enliven Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Exelixis	35.33%	42.17%	31.76%

Enliven Therapeutics presently has a consensus target price of $75.00, indicating a potential upside of 23.97%. Exelixis has a consensus target price of $50.07, indicating a potential downside of 9.40%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Enliven Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

In the previous week, Exelixis had 19 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Exelixis and 7 mentions for Enliven Therapeutics. Exelixis' average media sentiment score of 1.34 beat Enliven Therapeutics' score of 1.23 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38

Summary

Exelixis beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Enliven Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Enliven Therapeutics	N/A	-18.55%	-18.09%

BioMarin Pharmaceutical has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.92	$348.90M	$0.37	176.46
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 7 mentions for Enliven Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 1.32 beat Enliven Therapeutics' score of 1.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

BioMarin Pharmaceutical currently has a consensus price target of $88.79, indicating a potential upside of 36.00%. Enliven Therapeutics has a consensus price target of $75.00, indicating a potential upside of 23.97%. Given BioMarin Pharmaceutical's higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

BioMarin Pharmaceutical beats Enliven Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 9.87%. Enliven Therapeutics has a consensus price target of $75.00, indicating a potential upside of 23.97%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.23 beat Arrowhead Pharmaceuticals' score of 1.18 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enliven Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Enliven Therapeutics' return on equity of -18.55% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Arrowhead Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	15.04	-$1.63M	-$2.25	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

Arrowhead Pharmaceuticals and Enliven Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.46B	$4.04B	$7.31B	$12.78B
Dividend Yield	N/A	3.62%	2.53%	11.03%
P/E Ratio	N/A	6.53	210.50	22.08
Price / Sales	N/A	1,362.63	630.29	95.53
Price / Cash	N/A	108.46	79.17	53.57
Price / Book	4.95	16.47	13.01	6.26
Net Income	-$103.69M	-$22.76M	$3.46B	$348.07M
7 Day Performance	2.68%	3.31%	1.95%	1.40%
1 Month Performance	14.71%	11.58%	8.17%	4.59%
1 Year Performance	192.55%	58.36%	26.28%	17.05%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	2.9299 of 5 stars	$60.50 -0.6%	$75.00 +24.0%	+199.6%	$4.46B	N/A	N/A	50	Positive News
BBIO BridgeBio Pharma	3.2846 of 5 stars	$82.98 +3.9%	$100.79 +21.5%	+62.4%	$16.22B	$713.07M	N/A	400
ASND Ascendis Pharma A/S	4.48 of 5 stars	$248.85 +0.6%	$300.33 +20.7%	+27.3%	$15.52B	$814.57M	19.31	1,189	Analyst Forecast
EXEL Exelixis	3.3559 of 5 stars	$53.12 +1.5%	$50.07 -5.7%	+46.3%	$13.16B	$2.44B	16.70	1,077	Positive News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9078 of 5 stars	$66.99 +0.5%	$88.41 +32.0%	+14.2%	$12.97B	$3.41B	181.05	3,221	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Enliven Therapeutics compare to BridgeBio Pharma?

Summary

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Enliven Therapeutics compare to Exelixis?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Enliven Therapeutics compare to BridgeBio Pharma?

Is BBIO or ELVN more profitable?

Do analysts prefer BBIO or ELVN?

Do insiders & institutionals hold more shares of BBIO or ELVN?

Does the media prefer BBIO or ELVN?

Which has more volatility & risk, BBIO or ELVN?

Which has higher valuation and earnings, BBIO or ELVN?

Summary

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Which has more risk and volatility, ASND or ELVN?

Do institutionals and insiders have more ownership in ASND or ELVN?

Does the media prefer ASND or ELVN?

Which has higher valuation & earnings, ASND or ELVN?

Do analysts prefer ASND or ELVN?

Is ASND or ELVN more profitable?

Summary

How does Enliven Therapeutics compare to Exelixis?

Do institutionals and insiders believe in ELVN or EXEL?

Is ELVN or EXEL more profitable?

Do analysts rate ELVN or EXEL?

Which has more volatility & risk, ELVN or EXEL?

Does the media favor ELVN or EXEL?

Which has better earnings and valuation, ELVN or EXEL?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Do institutionals and insiders believe in BMRN or ELVN?

Is BMRN or ELVN more profitable?

Which has preferable earnings & valuation, BMRN or ELVN?

Does the media refer more to BMRN or ELVN?

Which has more risk & volatility, BMRN or ELVN?

Do analysts recommend BMRN or ELVN?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate ARWR or ELVN?

Does the media refer more to ARWR or ELVN?

Which has more risk and volatility, ARWR or ELVN?

Do insiders and institutionals believe in ARWR or ELVN?

Is ARWR or ELVN more profitable?

Which has better valuation & earnings, ARWR or ELVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools